Antihistamines are classified into two groups – the first-generation (“sedating”) and second-generation (“non-sedating”).
Sedating antihistamines cause sedation as they are highly lipid soluble and readily cross the blood brain barrier.
Examples of sedating antihistamines: Sedation is rare with non-sedating antihistamines, however patients should be made aware that a sedative effect may occur and performance of skilled tasks such as operating machinery or driving maybe affected.
Please see package insert for additional information and possible updates.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.
PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE.
BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
[ Read the disclaimer | Adults: Allergic rhinitis, seasonal/perennial: 5 mg po qd. In patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
Mechanism of Action Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity.
Receptor binding data indicate that at a concentration of 2–3 ng/m L (7 nanomolar), desloratadine shows significant interaction with the human histamine H1-receptor.
Desloratadine inhibited histamine release from human mast cells in vitro.
Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. Dosing: Oral: Children: 6-11 months: 1 mg once daily 12 months to 5 years: 1.25 mg once daily 6-11 years: 2.5 mg once daily Children /= 12 years and Adults: 5 mg once daily Supplied Syrup (Clarinex®): 0.5 mg/m L (480 m L) [bubble gum flavor] Tablet (Clarinex®): 5 mg Tablet, orally-disintegrating (Clarinex® Redi Tabs®): 5 mg [contains phenylalanine 1.75 mg/tablet] Adult (usual) Chronic idiopathic urticaria: 60 mg orally twice daily.
Seasonal allergic rhinitis: 60 mg orally twice daily or 180 mg once daily.